A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
Published date:
06/23/2021
Excerpt:
...successfully established a 5-genomic mutation signature that included CREBBP, KEAP1, RAF1, STK11 and TP53 mutations....The 5-genomic mutation signature could predict OS benefit for patients with NSCLC receiving atezolizumab.